Levamisole
Ergamisol (levamisole) is a small molecule pharmaceutical. Levamisole was first approved as Ergamisol on 1990-06-18. It is used to treat colonic neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levamisole hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ERGAMISOL | Johnson & Johnson | N-020035 DISCN | 1990-06-18 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| colonic neoplasms | — | D003110 | C18 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| S0177 | Levamisole hydrochloride, oral, 50 mg |
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Trichuriasis | D014257 | EFO_0007524 | B79 | — | — | — | 1 | — | 1 |
| Ascariasis | D001196 | EFO_0007154 | B77 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | — | — | 4 | — | — | 4 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 2 | — | — | 2 |
| Loiasis | D008118 | — | B74.3 | — | 2 | 1 | — | — | 2 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | 1 | — | — | 1 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | 1 | 1 | — | — | 1 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | 1 | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | — | 3 | — | — | 1 | 4 |
| Hemolytic anemia | D000743 | — | D55-D59 | — | 3 | — | — | — | 3 |
| Proteinuria | D011507 | HP_0000093 | R80 | — | 2 | — | — | — | 2 |
| Thrombosis | D013927 | — | — | — | 2 | — | — | — | 2 |
| Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | — | 2 | — | — | — | 2 |
| Bone marrow failure disorders | D000080983 | — | — | — | 2 | — | — | — | 2 |
| Hemoglobinuria | D006456 | — | R82.3 | — | 2 | — | — | — | 2 |
| Urination disorders | D014555 | — | — | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | — | 1 | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Levamisole |
| INN | levamisole |
| Description | Levamisole is a 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine. It has a role as an antinematodal drug, an antirheumatic drug, an immunomodulator, an immunological adjuvant and an EC 3.1.3.1 (alkaline phosphatase) inhibitor. It is an enantiomer of a dexamisole. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | c1ccc([C@H]2CN3CCSC3=N2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 14769-73-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1454 |
| ChEBI ID | 6432 |
| PubChem CID | 26879 |
| DrugBank | DB00848 |
| UNII ID | 2880D3468G (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Levamisole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,343 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
347 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use